These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36625424)

  • 1. Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease.
    Kurz C; Stöckl L; Schrurs I; Suridjan I; Gürsel SÜ; Bittner T; Jethwa A; Perneczky R
    J Neurochem; 2023 Apr; 165(1):95-105. PubMed ID: 36625424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.
    Gervaise-Henry C; Watfa G; Albuisson E; Kolodziej A; Dousset B; Olivier JL; Jonveaux TR; Malaplate-Armand C
    J Alzheimers Dis; 2017; 57(2):437-445. PubMed ID: 28269771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
    Bellomo G; Cataldi S; Paciotti S; Paolini Paoletti F; Chiasserini D; Parnetti L
    Alzheimers Res Ther; 2020 Sep; 12(1):121. PubMed ID: 32993776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration.
    Ashton NJ; Suárez-Calvet M; Karikari TK; Lantero-Rodriguez J; Snellman A; Sauer M; Simrén J; Minguillon C; Fauria K; Blennow K; Zetterberg H
    Alzheimers Dement (Amst); 2021; 13(1):e12168. PubMed ID: 34124336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.
    Palmqvist S; Stomrud E; Cullen N; Janelidze S; Manuilova E; Jethwa A; Bittner T; Eichenlaub U; Suridjan I; Kollmorgen G; Riepe M; von Arnim CAF; Tumani H; Hager K; Heidenreich F; Mattsson-Carlgren N; Zetterberg H; Blennow K; Hansson O
    Alzheimers Dement; 2023 Apr; 19(4):1204-1215. PubMed ID: 35950735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-Analytical Variables Influencing Stability of Blood-Based Biomarkers of Neuropathology.
    Panikkar D; Vivek S; Crimmins E; Faul J; Langa KM; Thyagarajan B
    J Alzheimers Dis; 2023; 95(2):735-748. PubMed ID: 37574735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group.
    Verberk IMW; Misdorp EO; Koelewijn J; Ball AJ; Blennow K; Dage JL; Fandos N; Hansson O; Hirtz C; Janelidze S; Kang S; Kirmess K; Kindermans J; Lee R; Meyer MR; Shan D; Shaw LM; Waligorska T; West T; Zetterberg H; Edelmayer RM; Teunissen CE
    Alzheimers Dement; 2022 Aug; 18(8):1484-1497. PubMed ID: 34845818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Long-Term Storage on the Reliability of Blood Biomarkers for Alzheimer's Disease and Neurodegeneration.
    Schubert CR; Paulsen AJ; Pinto AA; Merten N; Cruickshanks KJ
    J Alzheimers Dis; 2022; 85(3):1021-1029. PubMed ID: 34924380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease.
    Stevenson-Hoare J; Heslegrave A; Leonenko G; Fathalla D; Bellou E; Luckcuck L; Marshall R; Sims R; Morgan BP; Hardy J; de Strooper B; Williams J; Zetterberg H; Escott-Price V
    Brain; 2023 Feb; 146(2):690-699. PubMed ID: 35383826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dynamics of plasma biomarkers across the Alzheimer's continuum.
    Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
    Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a unified protocol for handling of CSF before β-amyloid measurements.
    Janelidze S; Stomrud E; Brix B; Hansson O
    Alzheimers Res Ther; 2019 Jul; 11(1):63. PubMed ID: 31324260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology.
    Sunde AL; Alsnes IV; Aarsland D; Ashton NJ; Tovar-Rios DA; De Santis G; Blennow K; Zetterberg H; Kjosavik SR
    Alzheimers Dement (Amst); 2023; 15(2):e12439. PubMed ID: 37192842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort.
    Amft M; Ortner M; Eichenlaub U; Goldhardt O; Diehl-Schmid J; Hedderich DM; Yakushev I; Grimmer T
    Alzheimers Res Ther; 2022 Apr; 14(1):60. PubMed ID: 35473631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals.
    Brum WS; Ashton NJ; Simrén J; di Molfetta G; Karikari TK; Benedet AL; Zimmer ER; Lantero-Rodriguez J; Montoliu-Gaya L; Jeromin A; Aarsand AK; Bartlett WA; Calle PF; Coşkun A; Díaz-Garzón J; Jonker N; Zetterberg H; Sandberg S; Carobene A; Blennow K
    Alzheimers Dement; 2024 Feb; 20(2):1284-1297. PubMed ID: 37985230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.
    Janelidze S; Palmqvist S; Leuzy A; Stomrud E; Verberk IMW; Zetterberg H; Ashton NJ; Pesini P; Sarasa L; Allué JA; Teunissen CE; Dage JL; Blennow K; Mattsson-Carlgren N; Hansson O
    Alzheimers Dement; 2022 Feb; 18(2):283-293. PubMed ID: 34151519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-Head Comparison of Different Blood Collecting Tubes for Quantification of Alzheimer's Disease Biomarkers in Plasma.
    Jiang L; Ding X; Wang W; Yang X; Li T; Lei P
    Biomolecules; 2022 Aug; 12(9):. PubMed ID: 36139033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
    Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
    Mattsson-Carlgren N; Grinberg LT; Boxer A; Ossenkoppele R; Jonsson M; Seeley W; Ehrenberg A; Spina S; Janelidze S; Rojas-Martinex J; Rosen H; La Joie R; Lesman-Segev O; Iaccarino L; Kollmorgen G; Ljubenkov P; Eichenlaub U; Gorno-Tempini ML; Miller B; Hansson O; Rabinovici GD
    Neurology; 2022 Mar; 98(11):e1137-e1150. PubMed ID: 35173015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.